Offbeat New Giant Contribution for BionTech
COVID 19 vaccine: BionTech expects early vaccine approval for children
12- 15-year-olds could soon be vaccinated against Corona. In the US, Biiontech filed an authorization request, in the EU, the next week should be the case. © DPA Even children could soon be vaccinated with the BionTech vaccine. In an approval study at 12- to 15-year-olds, there has been an efficacy of 100 percent. The first Corona vaccines for children in Europe could be available in a few weeks.
The Mainz vaccine pioneer biontech may be pleased: until 2023, the European Union buys a large scale Corona vaccine from the company and its partner Pfizer.
The EU Treaty for Buying up to 1.8 billion Other Corns Corona vaccine from BIONTECH / PFIZER is under the roof and subject. This communicated EU Commission Chef Ursula von der Leyen. The quantity should be delivered by 2023. 900 million cans should be ordered firmly, another 900 million cans are an option. This frenched vaccinations of adults and the 70 to 80 million children in the EU are immunized against the coronavirus.
COVID-19. Pfizer / Biontech requests the authorization of its vaccine for 12-15 years in the EU
© Benoit Tessier / Reuters A caregiver prepares a dose of vaccine Pfizer / Biontech in the center of Marne-la-Vallée, April 24 2021. The German-American laboratory filed an application for authorization for its Anticovid vaccine for young people aged 12 to 15 years. Results could be communicated within 4 to 6 weeks.
single dose below 20 Euro
The contract has a volume of up to 35 billion euros after information from the German press agency. This means further investments in Germany and Belgium. Although the EU Commission usually officially says nothing about the cost of the purchased vaccines. According to DPA information, the agreed price per dose is on the order of magnitude that Bulgaria's Prime Minister Bookbo Borissow had recently called: about 19.50 euros per dose. The price of 23.50 euros mentioned in media reports is too high, it was in Brussels. The sum per dose is "under 20 euros".
As out of a letter from the Federal Ministry of Finance to the Budget Committee of the Bundestag, Germany could relate 165 million doses from the order of the first 900 million doses. The costs are therefore 3.83 billion euros.
Canadians should weigh risk of rare blood clots from Johnson & Johnson vaccine with COVID-19 risk, NACI says
Health Canada approved the J&J vaccine in March and updated its labelling last week to acknowledge the risk of a rare but blood-clotting condition.The National Advisory Committee on Immunization (NACI) said Monday that while the Johnson & Johnson vaccine will soon be distributed across Canada, it's up to Canadians to decide whether they should take it or wait for an mRNA vaccine such as Pfizer-BioNTech or Moderna.
The EU Commission defended that the price will be higher than the previous treaties with BiionTech / Pfizer. There are stricter delivery agreements, other liability rules and agreements on the adaptation of the vaccine to new virus variants, it was from the authority. In addition, the EU will not pay any more money for production promotion in the future.There is still an opposition period
from the Leyen announced on April 14, that the German company Biiontech and its US partner Pfizer is negotiated on the delivery of the giant quantity. The talks then pulled themselves longer than thought. According to reports, France had objections. Ultimately, however, all 27 EU states supported the deal. Now still officially runs a dispute period of five working days until the signature can be set under the contract.
The EU Commission expects that around 700 million doses are necessary for refreshments and vaccination by children 2022 and 2023. If a mutation of the coronavirus occurs against which the previous vaccinations do not help, they would need 640 million doses to completely remunize 70 percent of the EU population.
For the ongoing vaccination campaign, the EU already has two framework contracts with BionTech / Pfizer over 600 million vaccases that are gradually delivered since the end of 2020. From the beginning of April to the end of June, the EU expects 250 million vaccine doses. Their mRNA vaccine was the first to be admitted in Europe. He is considered very effective and very safe.
HAZ / BRI / DPA, AFP)
BIONTECH generates quarterly profit of 1.1 billion euros .
The Mainz Corona vaccine manufacturer BIONTECH has achieved a quarterly profit of 1.1 billion euros in the first quota of this year. © Klaus-Dietmar Gabbert / DPA Central Image / DPA The Mainz Corona vaccine manufacturer BIONTECH has achieved a quarterly profit of 1.1 billion euros in the first quota of this year. compared to the fourth quarter of 2020 (366.9 million), according to the company from Monday, a tripling of the net profit means.